Drugs & Pharmaceuticals

Press briefings, by any measure, are long and loud. And now they may get longer and louder since there is another potential antiviral drug to yell about. 

I thought that this would be a good time to review the various vaccines and therapies being studied to combat the coronavirus pandemic.

By Katherine Seley-Radtke, University of Maryland, B

In the next few weeks, we will experience the downside risks of offshoring. Moving manufacturing to areas with specialized expertise should reduce costs and provide a better product.

On March 23 Arizona Governor Doug Ducey sent a letter to Seema Verma, Administrator of the Centers for Medicare and Medicaid Services, informing

Within the coming weeks, we should be starting to get a picture of whether remdesivir will be a savior to the world, just another failed drug, or something in between.

Coronaviruses are a large family of viruses that cause disease in animals and humans.

Two drugs, chloroquine (CQ), and hydroxychloroquine (HCQ) are all over the news because both drugs are being extensively studied for their antiviral potential against coronavirus.

You just can't hype drugs. They are either going to work well or not. Wishful thinking doesn't help. Neither does bluster. Nonetheless, we're now getting quite a dose of hype and bluster in recent days.

There is now a potentially important change in the pharmaceutical landscape of anti-coronavirus drugs.